GlycoVaxyn is building a portfolio of bioconjugate vaccine candidates based on glycoproteins that have the ability to produce a strong immune response. These candidates target some of the most common and severe bacterial infections that occur in childhood and continue throughout life.

GlycoVaxyn has several vaccines under development with its lead candidates in pre-clinical development, serving as proof-of-concept for the technology. Next steps will involve the establishment of a GMP production process, toxicology studies and Phase I studies in 2009.